Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Gene Logic Inc. (NASDAQ:GLGC) announced today that it completed the sale of its Genomics assets to Ocimum Biosolutions Ltd., a global life sciences R&D enabling company. As a...
Gene Logic Inc. (NASDAQ:GLGC) announced today that the Company?s shareholders have approved both the sale of its Genomics Assets to Ocimum Biosolutions and the renaming of the...
Gene Logic Inc. (NASDAQ:GLGC) announced today the appointment of Stephen R. Donahue, M.D. as Senior Vice President of Clinical Development. Dr. Donahue will lead the Company?s...
Gene Logic Inc. (NASDAQ: GLGC) announced today that GL1001, the company?s clinical-stage drug candidate, showed indications of efficacy at relevant doses in in vivo testing for...
Gene Logic Inc. (NASDAQ: GLGC) today reported financial results for the second quarter ended June 30, 2007. Q2 Highlights Highlights for the second quarter of 2007...
Gene Logic Inc. (NASDAQ:GLGC) announced today that it will release second quarter 2007 financial results on Friday, July 27, 2007 at 6:00 a.m. Eastern Time, before the open of...
Gene Logic Inc. (NASDAQ:GLGC) announced today that it has entered into a drug repositioning and development agreement with H. Lundbeck A/S to seek alternative development paths...
Gene Logic Inc. (NASDAQ:GLGC) announced today that a collaborative study between its Genomics Division and Mayo Clinic has found biomarkers that predict susceptibility to...
Gene Logic Inc. (NASDAQ:GLGC) announced today that it has entered into an agreement with Abbott to seek additional development paths for multiple Abbott drug candidates. All of...
Gene Logic Inc. (NASDAQ:GLGC) today reported financial results for the first quarter ended March 31, 2007. Revenue Revenue for Gene Logic?s continuing operations is...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
